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Abstract 
Background: Disruption of the endothelial glycocalyx (eGC) is observed in septic 
patients and its injury is associated with multiple-organ failure and inferior outcomes. 
Besides this biomarker function, increased blood concentrations of shedded eGC 
constituents might play a mechanistic role in septic organ failure. We hypothesized 
that therapeutic plasma exchange (TPE) using fresh frozen plasma might influence 
eGC-related pathology by removing injurious mediators of eGC breakdown while at 
the time replacing eGC protective factors.
Methods: We enrolled 20 norepinephrine-dependent (NE > 0.4 μg/kg/min) patients 
with early septic shock (onset < 12 h). Sublingual assessment of the eGC via sublingual 
sidestream darkfield (SDF) imaging was performed. Plasma eGC degradation products, 
such as heparan sulfate (HS) and the eGC-regulating enzymes, heparanase (Hpa)-1 and 
Hpa-2, were obtained before and after TPE. A 3D microfluidic flow assay was per-
formed to examine the effect of TPE on eGC ex vivo. Results were compared to healthy 
controls.
Results: SDF demonstrated a decrease in eGC thickness in septic patients compared 
to healthy individuals (p = 0.001). Circulating HS levels were increased more than sixfold 
compared to controls and decreased significantly following TPE [controls: 16.9 (8–18.6) 
vs. septic patients before TPE: 105.8 (30.8–143.4) μg/ml, p < 0.001; vs. after TPE: 70.7 
(36.9–109.5) μg/ml, p < 0.001]. The Hpa-2 /Hpa-1 ratio was reduced in septic patients 
before TPE but normalized after TPE [controls: 13.6 (6.2–21.2) vs. septic patients at 
inclusion: 2.9 (2.1–5.7), p = 0.001; vs. septic patients after TPE: 13.2 (11.2–31.8), p < 0.001]. 
Ex vivo stimulation of endothelial cells with serum from a septic patient induced eGC 
damage that could be attenuated with serum from the same patient following TPE.
Conclusions: Septic shock results in profound degradation of the eGC and an 
acquired deficiency of the protective regulator Hpa-2. TPE removed potentially injuri-
ous eGC degradation products and partially attenuated Hpa-2 deficiency.
Trial registration clinicaltrials.gov NCT04231994, retrospectively registered 18 January 
2020
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Take-home message
Septic shock results in profound degradation of the endothelial glycocalyx (eGC) and 
an acquired deficiency of the protective regulator Heparanase-2 (Hpa-2). Therapeutic 
plasma exchange removed injurious eGC degradation products and partially attenu-
ated Hpa-2 deficiency.
Background
Sepsis is a clinical syndrome characterized by life-threatening organ dysfunction caused 
by a dysregulated host response to infection. Septic shock features hypotension refrac-
tory to volume resuscitation and serum lactate elevation [1] commonly ending in death 
[2]. It has been recognized that global endothelial dysfunction, in particular breakdown 
of the vascular barrier, represents a cornerstone in the development of multi-organ fail-
ure in sepsis [3]. The endothelial glycocalyx (eGC), a gel-like structure of glycosami-
noglycans and proteoglycans covering the entire luminal surface of the endothelium, 
contributes to the maintenance of vascular hemostasis including tone and permeability 
as well as inflammation and coagulation [4]. Disruption of this highly dynamic structure 
is observed early in sepsis, and the resultant eGC injury is strongly associated with later 
multi-organ failure and inferior outcomes [5–7]. Heparanase-1 (Hpa-1) is the enzyme 
primarily responsible for the injurious degradation of the major eGC component, hep-
aran sulfate (HS), and is upregulated in sepsis [8]. By contrast, Heparanase-2 (Hpa-2), a 
protein that has been described as a protective antagonist of Hpa-1 [9, 10], is suppressed 
in murine sepsis models [11], suggesting imbalance of eGC-regulating proteins in sep-
sis. Furthermore, increased levels of shedded HS degradation products into the circula-
tion are not only biomarkers of glycocalyx injury, but also can act as disease mediators, 
namely the so-called Damage associated molecular patterns (DAMPs), directly con-
tributing to sepsis-associated organ failures such as cardiomyopathy [12] and encepha-
lopathy [13]. Therapeutic efforts against sepsis morbidity and mortality are limited to 
anti-infectious measures (including antimicrobials and surgical or interventional focus 
sanitation) and organ support [14]. So far, no specific intervention targeting endothelial 
dysfunction, including eGC degradation, exists to the present time. Therapeutic plasma 
exchange (TPE) has been recently investigated as a potential adjunctive treatment strat-
egy in early and severe septic shock [15]. The observed positive effects in rapid hemo-
dynamic stabilization [15] could be related to removal of deleterious components or 
replacement of protective plasma proteins consumed by the disease process [16, 17].
Here, we hypothesize that TPE against plasma from healthy donors might (1) 
remove products of eGC shedding that serve as injurious DAMPs (e.g., HS) and (2) 
simultaneously compensate deficiency of protective Hpa-2 to attenuate imbalance of 
eGC regulation enzymes. In this study, we therefore investigated the effect of a sin-
gle TPE against fresh frozen plasma (FFP) on key constituents of the eGC as well its 
regulating enzymes in the blood of patients with early and severe septic shock. Addi-
tionally, quantitative sublingual sidestream darkfield (SDF) imaging in vivo as well as 
microvascular perfusion studies in an ex  vivo endothelial microfluidic chip model, 
were undertaken to test our hypothesis.
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Methods
Study population
This study was a post hoc analysis from a subset of patients included in both a sin-
gle-center non-randomized study [15] and a recently concluded randomized study 
(NCT04231994, accepted for publication, unpublished). Data and bio-samples were 
acquired from patients receiving TPE directly before and after the TPE procedure 
and results were further compared to healthy individuals used as controls. In total, 
we screened 1.427 patients submitted to our 14-bed medical ICU from July 2016 to 
March 2019 for the presence of sepsis using the SEPSIS-3 definition [1]. Of the 45 
patients included in both studies, we finally analyzed a subgroup of 20 patients, all of 
whom received additional TPE treatment and provided sufficient blood sample vol-
umes for all further analysis steps (Fig. 1). All patients were treated according to the 
2016 Surviving Sepsis Campaign (SSC) guidelines. Patients were included based on: 
(i) septic shock with need for vasopressors < 24  h prior to entry, and (ii) profound 
systemic hypotension requiring norepinephrine (NE) doses of > 0.4 µg/kg/min despite 
adequate intravenous fluid resuscitation (≥ 30  ml/kg bodyweight crystalloids). As 
exclusion criteria, we defined unavailability of TPE within first 6 h after study inclu-
sion, pregnancy or breast feeding, age < 18  years, end-stage chronic disease, and 
presence of a directive to withhold life-sustaining treatment. The ethical committee 
1427 patients screened
between July 2016- March 2019 
441 patients with sepsis
(Sepsis-3 criteria) 
45 patients with septic shock
< 24 hrs and
NE dose > 0.4 ug/kg/min 
20 patients analyzed
986 had a non-infectious
condition requiring intenive care 
164 patients had sepsis w/o shock
145 patients had shock > 24 hrs 
87 patients had NE dose < 0.4 ug/kg/min 
76 patients had shock > 24 hrs + NE <  
    0.4 ug/kg/min) 
4 patients had no blood collected before
and after TPE 
11 patients had blood collected but  
it was used completely for other
investigations
10 patients received no TPE (as part of
randomization in the second study) 
Fig. 1 Flowchart of study participants. NE means norepinephrine and TPE therapeutic plasma exchange
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of Hannover Medical School approved both study protocols (EK 2786-2015 and EK 
8852_MPG_23b_2020) and written informed consent was obtained from participants 
or authorized representatives. The study was performed in accordance with the ethi-
cal standards laid down in the 1964 Declaration of Helsinki and its later amendments. 
Demographic and clinical data were obtained immediately at study inclusion before 
TPE. For comparison, following informed consent, 20 healthy controls without pre-
existing medical conditions were included into the study.
TPE
Vascular access was established by venous insertion of an 11-French two-lumen 
hemodialysis catheter. TPE was performed in a singular treatment session against 
a fixed dose of 12 units of FFP. All patients received single shot triple anti-allergic 
prophylaxis with 100 mg decortin, 2 mg clemastine (H1 inhibitor) and 50 mg raniti-
dine (H2 inhibitor), given intravenously directly before start of the TPE treatment. 
Anticoagulation during TPE was achieved by regional citrate infusion. 11/20 (55%) 
of patients received additional prophylactic anticoagulation by continuous low dose 
(median (IQR) 400 (400–800)  IU/h) heparin. In patients with acute kidney injury 
(AKI), hemodialysis was interrupted for the duration of TPE. Blood samples were 
drawn before and after TPE. NE dose was titrated every 10–15  min to maintain a 
mean arterial pressure (MAP) above 65 mmHg.
Data and sample collection
Patient plasma and serum blood samples were acquired before and after TPE and 
therefore time elapsed between both blood draws was short (3 ± 1.5  h). For compari-
son, we used plasma and serum from healthy human donors without pre-existing seri-
ous medical conditions after written informed consent. Plasma samples were collected 
in non-heparinized tubes. No personal or identifying information were collected from 
study participants. All samples were stored at – 80 °C until use. All personal patient data 
were anonymized before further analysis. Data were collected using electronic medical 
records including the patient data monitoring system (PDMS) m.life (Version 10.5.0.71, 
medisite GmbH, Berlin, Germany). Sequential Organ failure Assessment (SOFA) scores 
were calculated according to the description by Vincent et al. [18].
Assessment of the eGC thickness in vivo
The eGC thickness was assessed non-invasively using a SDF camera (CapiScope 
HVCS, KK Technology, Honiton, UK) coupled with the GlycoCheck™ software. The 
software automatically detects microvessels with diameters between 5 and 25 µm and 
records eGC thickness, determined by analysis of the dynamic lateral movement of 
red blood cells into the permeable part of the eGC layer expressed as the Perfused 
boundary region (PBR) (in µm). All measurements were performed at the time of 
blood sampling before initiation of TPE by observers experienced in the method as 
described before [6]. Three consecutive measurements were taken and then averaged.
Page 5 of 16Stahl et al. Intensive Care Medicine Experimental            (2021) 9:57  
Enzyme‑linked immunosorbent assays
ELISAs specific for Heparanase-1 (amsbio, #EA1340Hu) and Heparanase-2 (amsbio, 
#E5389Hu) were performed in plasma samples. All samples were measured using a 
Tecan absorbance microplate reader (Sunrise, #F039300) at 450  nm. All measure-
ments were performed in duplicates. Hyaluronan concentration was measured using 
the Hyaluronan DuoSet ELISA according to manufacturer’s instruction (R&D Sys-
tems, Wiesbaden, Germany).
Glycosaminoglycan isolation and purification
The plasma samples were diluted 1:1 in 0.1 M  K2HPO4 (pH 8.0) and then subjected 
to proteolysis with 100 µg/ml proteinase K (Sigma-Aldrich, Darmstadt, Germany) at 
56 °C for 24 h. Afterwards, the samples were heated at 90 °C for 10 min and filtrated 
on Ultrafree-MC filters (0.22  µm membrane) at 12,000g for 10  min. Filtrates were 
recovered, mixed with equal amounts of 1.5% sodium nitrate and 33% of acetic acid, 
and incubated at room temperature with gentle shaking for 1  h. The reaction was 
stopped by the addition of 12.5% ammonium sulfate (half of a total sample volume). 
Subsequently, the samples were transferred to the tubes containing saline and Triton 
X-100 (final concentration 1%), vigorously shacked at room temperature for 30 min 
and then cooled down to 4 °C using ice bath. Finally, the samples were supplemented 
with trichloroacetic acid to the final concentration of 10% at incubated at 4  °C for 
additional 10 min, followed by centrifugation at 12.000g for 10 min and washing with 
chloroform. The aqua phase was dialyzed (3500 MWCO) against buffer containing 
40 mM ammonium acetate and 3 mM  CaCl2 (pH 6.8) for 16 h. The glycosaminogly-
cans were collected and either directly subjected to digestion or lyophilized.
Enzymatic digestion of glycosaminoglycans and liquid chromatography–mass 
spectrometry (LC–MS) analysis
The glycosaminoglycans were digested with 0.1 U/ml chondroitin lyase ABC (Sigma-
Aldrich, Darmstadt, Germany) in 40  mM ammonium acetate and 3  mM  CaCl2 (pH 
6.8) at 37 °C overnight. The digestion products were recovered by centrifugal filtration 
(3500 MWCO) and freeze-dried for LC–MS analysis. Alternatively, glycosaminogly-
cans were treated with 1 U/ml of heparinase enzymes (Iduron, ALderley Edge, United 
Kingdom) at 30 °C for 10 h or with 60 U/ml hyaluronidase (Sigma-Aldrich) 37 °C for 
6 h. Derivatization of unsaturated disaccharides with 2-aminoacridone (AMAC) and 
LC–MS analysis were performed as previously described [19].
Microfluidic experiments
Microfluidic chips were fabricated of polydimethylsiloxane (PDMS) (Sylgard 184, 
Dow Corning) by replication of the polymeric master as described by our group pre-
viously [11]. Naive human microvascular endothelial cell (HMEC-1) line (ATCC) 
was incubated in MCDB131 medium under flow conditions (38.75  dyn/cm2) for 
5 days before the experiments. Then, cells were treated with medium supplemented 
with 10% serum from one representative patient (collected before and directly after 
TPE and taken directly to the perfusion system) or control serum (pooled from four 
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healthy controls) for 6  h under flow conditions. The cells were fixed with 4% PFA 
under flow. Then, chips were disconnected from the flow and cells were permeabilized 
with 0.1% Triton X-100/PBS and stained using anti-heparan sulfate antibody (Ams-
bio, 10E4260917, dilution: 1:100) and as a secondary antibody for confocal micros-
copy anti-mouse-alexa 633 (ThermoFisher Science, A21056, dilution: 1:500). Confocal 
microscopy was then performed without flow using Leica TCS-SP2 AOBS confocal 
microscope (Leica Microsystems) at the Core Facility for Laser Microscopy at Hanno-
ver Medical School. All the images were taken with oil-immersed ×63 objective, NA 
1.4. Series of z-scans were processed and quantified using ImageJ software. 3D recon-
struction of the eGC structure was performed using Leica LasX software.
Statistical analysis
Data were presented as median with interquartile range (IQR). Two-tailed p values of 
less than 0.05 were considered to indicate statistical significance. Paired t-test or Wil-
coxon test (as appropriate) was utilized in order to compare longitudinal values before 
(pre) and after (post) TPE. Unpaired t-test and Mann–Whitney test (for not normal 
distributed variables) were employed to compare unpaired values. We used GraphPad 
Prism 7 (Graph Pad, La Jolla, CA, USA) and SPSS Statistics Version 25 (SPSS Inc., Chi-
cago, IL, USA) for data analysis and graph generation.
Results
Cohort characterization
Demographic and clinical details are summarized in Table  1. Eighty percent of the 
patients were men, and the median (IQR) age was 53 (34–59) years. Lungs and the abdo-
men were the most common sites of infection. A causative pathogen was identified in 
65% of the cases. Gram negative and positive pathogens were most commonly identi-
fied and in 10% more than one pathogen was detected. All patients were treated with a 
combination of broad-spectrum antibiotics. Median (IQR) SOFA score was 18 (15–19). 
All patients were in severe shock indicated by high NE doses and lactate concentrations 
at study inclusion. Patients displayed signs of severe hyper-inflammation as indicated by 
high levels of C-reactive protein (CRP) and procalcitonin (PCT). Ninety percent were 
mechanical ventilated and had an oxygenation index  (PaO2/FiO2) of 130 (117–189). AKI 
with need for renal replacement therapy (RRT) was present in 65% of the patients at 
time of inclusion.
Assessment of endothelial glycocalyx thickness in vivo
We quantified the size of the individual patients’ eGC in the sublingual microvasculature 
using an indirect surrogate termed PBR. The larger the PBR (i.e., the diameter where 
the blood cells move in a micro-vessel), the smaller the thickness of the eGC. We found 
(Fig. 2) a decrease in the thickness of the eGC in septic patients compared to healthy 
individuals indicated by increased PBRs [median (IQR) PBR for controls: 1.88 (1.82–
1.93) μm vs. septic patients at inclusion: 2.18 (2.06–2.48) μm, p = 0.001]. In a representa-
tive video recording, almost complete stasis of microvascular blood flow can be seen 
at study inclusion, which was improved in a repetitive recording directly following TPE 
treatment (Additional file 1: Video S1 and Additional file 2: Video S2).
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Effect of TPE on products of endothelial glycocalyx shedding
Three key constituents of the eGC were investigated in the patients’ blood employ-
ing mass spectroscopy analysis (Fig.  3). Chondroitin sulfate (CS) concentrations 
(Fig.  3A) were increased at study inclusion compared to healthy controls but were 
not significantly reduced following TPE (controls: 7.1 (6.3–7.7)  μg/ml vs. septic 
patients at inclusion: 9.3 (6.5–35.5)  μg/ml, p = 0.005; vs. septic patients after TPE: 
8.5 (6–30.8) μg/ml, p = 0.078). HA (Fig. 3B) was increased in septic individuals and 
reduced by more than half following TPE (controls: 10.1 (5.8–17.4) ng/ml vs. septic 
patients at inclusion: 1476 (188.3–3834) ng/ml, p < 0.001; vs. septic patients after TPE: 
652.9 (146.1–1592) ng/ml, p < 0.001). Comparable, HS (Fig. 3C) concentrations were 
increased more than six times compared to controls and were decreased by about 
a third following a single TPE treatment (controls: 16.9 (8–18.6)  μg/ml vs. septic 
Table 1 Demographic and clinical characteristics at baseline
Given are demographic and clinical characteristics at the time of study inclusion before therapeutic plasma exchange (TPE) 
treatment. Values are presented as median (25% to 75% interquartile range) or if categorical as numbers and percentages. 
Demographic characteristics for the control patients were: median (IQR) age 50 (28–63) years and 15/20 males for laboratory 
investigation controls; 39 (36–44) years and 5/10 males for SDF measurement controls. All individuals of the control cohorts 
had no relevant medical preconditions
BMI body mass index, SOFA Sequential Organ Failure Assessment, CRP C-reactive protein, PCT procalcitonin
Category Median (IQR)/n (%)
Age—year 53 (34–59)
Sex—no (%)
 Male 16 (80)
 Female 4 (20)
BMI—kg/m2 27.8 (21.9–32.6)
Sepsis onset—no (%)
 Ambulatory 14 (70)
 Hospital acquired 6 (30)
Side of infection—no (%)
 Lung 14 (70)
 Abdomen 3 (15)
 Urogenital 1 (5)
 Soft tissue 1 (5)
 More than one 1 (5)
Identified pathogen—no (%)
 Gram+ 3 (15)
 Gram− 6 (30)
 Fungi 1 (5)
 Viral 1 (5)
 More than one 2 (10)
 Non-identified 7 (35)
SOFA 18 (15–19)
Norepinephrine dose (μg/kg/min) 0.734 (0.564–1.206)
CRP (mg/l) 267 (151–325)
PCT (μg/l) 24 (9–99)
Lactate (mmol/l) 6.6 (2.6–11.3)
Mechanical ventilation—no (%) 18 (90)
Oxygenation index  (PaO2/FiO2) 130 (117–189)
Renal replacement therapy—no (%) 13 (65)
Page 8 of 16Stahl et al. Intensive Care Medicine Experimental            (2021) 9:57 
patients at inclusion: 105.8 (30.8–143.4) μg/ml, p < 0.001; vs. septic patients after TPE: 
70.7 (36.9–109.5) μg/ml, p < 0.001).
Effect of TPE on regulating enzymes of the endothelial glycocalyx
The key glycocalyx sheddase Hpa-1 (Fig.  4A) was decreased in septic shock patients 
compared to controls and increased following TPE [controls: 1.8 (1.2–2.7)  ng/ml vs. 
septic patients at inclusion: 1 (0.9–1.3)  ng/ml, p < 0.001; vs. septic patients after TPE: 
1.3 (1.2–1.7)  ng/ml, p < 0.001]. Even more noticeable, the Hpa-1 counterpart, Hpa-2 
(Fig.  4B), was reduced by 85% in septic patients compared to non-septic individuals 
and was substituted by TPE treatment reaching normal blood concentrations following 
TPE [controls: 16.7 (10.6–31.1) U/ml vs. septic patients at inclusion: 2.5 (2.2–5.9) U/ml, 
p < 0.001; vs. septic patients after TPE: 19.7 (13.8–39.8) U/ml, p < 0.001]. Consequentially, 
the ratio of Hpa-2 to Hpa-1 (Fig. 4C) concentration was reduced in septic patients before 
TPE and normalized after TPE [controls: 13.6 (6.2–21.2) vs. septic patients at inclusion: 
2.9 (2.1–5.7), p = 0.001; vs. septic patients after TPE: 13.2 (11.2–31.8), p < 0.001].
In vitro proof‑of‑concept experiment using a microfluidic chip model
To demonstrate that the degradation of the eGC induced by septic serum might be 
attenuated following TPE treatment, we used a microfluidic chamber with cultured 
endothelial cells under flow over 3  days that synthesize an intact and stable eGC 
under in vitro conditions. After stimulation with serum from a representative septic 
patient before and after TPE treatment or control serum, the eGC was visualized by 
confocal microscopy followed by computerized 3D reconstruction (Fig. 5A). The per-
centage of surface area covered with HS rich eGC is then quantified by analyzing the 
HS positive area. We found that stimulation with serum from a representative patient 
with septic shock before TPE was sufficient to severely damage the eGC indicated by 
a reduced HS positive area on the surface of endothelial cells (Fig. 5A). The HS posi-
tive area (Fig. 5B) was reduced by 37% compared to healthy controls (p = 0.003). Con-




















Fig. 2 Injury to the endothelial glycocalyx (eGC) in vivo. Sublingual dark field imaging in patients 
allows quantification of the eGC thickness as indicated by the perfused boundary region (PBR). Box and 
whisker plots showing results for healthy controls (n = 10) as well as patients with septic shock before 
commencement of therapeutic plasma exchange (TPE) (n = 11)
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Hpa-2 in septic patients, we observed that loss of HS positive area on endothelial cells 
was attenuated following perfusion with serum collected from the same patient after 
receiving TPE (Fig. 5A). Quantitative analysis demonstrated a trend towards higher 
HS surface areas when stimulation with serum collected pre- (3.7 ± 1.4%) and after 
(6.2 ± 3.7%) TPE were compared (p = 0.086 for pre vs. post-TPE, p = 0.948 for post-
TPE vs. control, Fig. 5B).
















































































Fig. 3 Effect of therapeutic plasma exchange (TPE) on glycocalyx shedding products. Box and whisker plots 
showing blood concentrations of hyaluronic acid (HA) (A), chondroitin sulfate (CS) (B) and heparan sulfate 
(HS) (C) for healthy controls (n = 20) as well as patients with septic shock before (pre) (n = 20) and directly 
after (post) (n = 20) TPE
Page 10 of 16Stahl et al. Intensive Care Medicine Experimental            (2021) 9:57 
Discussion
We investigated the effects of early TPE on the eGC in septic shock. Patients included 
in this investigation experienced a severe form of septic shock as indicated by high NE 



























































Fig. 4 Effect of therapeutic plasma exchange (TPE) on key regulating enzymes of the endothelial glycocalyx 
(eGC). Box and whisker plots showing blood concentrations of circulating Heparanase-1 (Hpa-1) (A), 
Heparanase-2 (Hpa-2) (B) as well as the ratio of Hpa-2 to Hpa-1 (C) for healthy controls (n = 18) as well as 
patients with septic shock before (pre) (n = 20) and directly after (post) (n = 20) TPE
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found that a single and early TPE had a profound effect on multiple different eGC-
related parameters in these patients and report several relevant findings.
First, we could confirm a profound decrease in eGC thickness, indicating shed-
ding of the eGC in septic patients compared to healthy controls by in vivo SDF meas-
urement. PBR values in this cohort were in line with previous observations made in 




































































Fig. 5 Ex vivo stimulation of 3D microvessels with septic serum before and after therapeutic plasma 
exchange (TPE). Exemplary 3D reconstruction of the heparan sulfate (HS) layer images of naive endothelial 
cells in a microfluidic chip (HS in red, DAPI nuclei staining in blue) after perfusion with serum and incubation 
overnight of a representative septic patient both before and after TPE compared to healthy control serum 
(pooled out of four control patients) (A) and quantification of the HS positive surface area as box and whisker 
plots (B)
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septic patients [20]. Of note, median PBR values were exclusively found in a range 
that was previously demonstrated to correlate with a poor survival in sepsis patients, 
namely a value above 1.97 μm [21].
Second, three key constituents of the eGC, notably CS, HA and HS, were increased 
in the circulation of septic shock patients and two of them (HA and HS) could be 
decreased by TPE. Among them, CS was only mildly increased, which is in line with 
previous observations [19, 22]. In contrast, both HA and HS were substantially ele-
vated in patients with sepsis. Considering the severity of septic shock in this cohort, 
these results reproduce previous observations that have closely correlated both HA 
and HS concentration to the severity of multi-organ dysfunction and mortality [6]. 
HA and HS, beyond being biomarkers of disease severity, have further been suggested 
to possess direct pathophysiological significance. HA causes amplification of the pro-
inflammatory response through Toll-like receptor-4 (TLR4) [23, 24]. HS aggravate 
systemic septic inflammatory reaction by increasing signaling through TLR4 [11, 25] 
and stabilization of interferon-gamma [26], potentially contributing to distant organ 
failure such as septic cardiomyopathy [12, 27]. Additionally, septic encephalopathy 
may be aggravated by direct binding of HS to protective neurotransmitters causing 
depletion of those within the central nervous system [13, 28]. Here, we could demon-
strate that TPE might be an effective tool to rapidly eliminate circulating HA and HS 
in septic patients.
Third, TPE attenuated an acquired imbalance of essential eGC regulation enzymes. 
The process of eGC degradation—leading to subsequent appearance of toxic shedding 
products in the patients’ blood—is closely regulated by specific enzymes. We inves-
tigated whether or not TPE could also affect these underlying regulatory enzymes. 
As HS is the most abundant constituent of the eGC and its role as a toxic DAMP 
has been described most extensively, we chose to focus on HS. Hpa-1 is primarily 
responsible for degradation of HS chains, and its enzymatic activity was increased 
in septic pulmonary [5] and renal [7] failure. While some previous reports found the 
concentration of Hpa-1 increased [12] in the blood of septic patients, others observed 
reduced blood concentrations of Hpa-1 [29]. In our study, Hpa-1 concentrations were 
significantly reduced compared to healthy controls. Given the close binding of Hpa-1 
within the HS rich layer eGC on inflammatory stimuli [30], one could speculate that a 
reduced Hpa-1 blood concentration might indicate an increased shift of Hpa-1 from 
the soluble compartment to the eGC layer leading to increased shedding of HS.
Previous observations found the protective antagonist, termed Hpa-2, to be depleted 
in septic mice blood and renal tissue [11]. Here, we confirm these pre-clinical findings 
for the first time in septic patients. An analogous role of acquired Hpa-2 deficiency in 
critical ill Covid-19 patients has been recently reported by our group [31]. In the pre-
sent study, TPE did not only replenish deficient Hpa-2, but completely corrected the 
imbalanced ratio of protective Hpa-2 to injurious Hpa-1. We speculate that correcting 
the balance of regulating mediators of critical HS content might translate into improved 
eGC stability under septic conditions. This observation suggests that TPE might evolve 
its therapeutic potential in sepsis not only by removing injurious molecules but also by 
replacing consumed protective factors. A similar state-of-affairs has been demonstrated 
earlier for proteins implicated in anticoagulation [16, 17].
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Finally, we applied a 3D ex vivo model using septic serum. This stimulus was sufficient 
to severely damage the eGC in a microfluidic chamber with cultured endothelial cells 
that synthesize an intact and stable eGC under in vitro conditions. Stimulation of this 
complex ex vivo cellular system with septic serum led to an acute degradation of HS. We 
suggest that this model represents an experimental correlate of the shedding exhibited 
by our patients. When we used serum from the same septic shock patients after TPE was 
performed, the eGC was protected in this in  vitro model. These observations suggest 
that TPE might reduce eGC shedding by rebalancing the homeostasis between Hpa-1/
Hpa-2.
Together, our data propose that TPE might indeed combine two important effects in 
one singular intervention—removing excessive injurious mediators (e.g., HS degrada-
tion products that serve as DAMPs) while at the same time replacing protective but con-
sumed factors (e.g., Hpa-2). In line with these observations, we have elaborated on this 
two-edged concept [17] previously concerning factors of inflammation/anti-inflamma-
tion [15, 32], pro-/anticoagulation [16] as well as endothelial permeability/ant-permea-
bility [15].
This study has several limitations, mainly its small sample size as well as the retro-
spective nature, and should therefore be assessed as primarily hypothesis generating. 
SDF measurement was only feasible in a subset of patients, mainly due to patient and 
caregiver specific limitations (e.g., prone positioning). This clearly might affect reliabil-
ity of PBR measurement. The in vitro investigation demonstrated data from a singular 
exemplary patient since usage of fresh patient serum appears to be essential to yield 
eGC degradation following microfluidic experiments. In addition, the intervention was 
administered at a fixed dose, which precludes us from providing data on effects at dif-
ferent dosages or time frames. Given the post hoc nature of this analysis, longitudi-
nal assessment of glycocalyx related parameters was not possible. For instance, PBR 
was not analyzed in the following days when de novo synthesis might have generated 
novel glycocalyx sugars. The restoration of a hydrodynamically relevant glycocalyx layer 
in vivo requires about 7 days [33]. It is therefore not to be expected that eGC thickness 
can improve within a short period of time. It has been demonstrated before, that cer-
tain heparan sulfate fragments induce septic encephalopathy in a length- and sulfation-
dependent manner [13], however an additional in depth analysis of fragment length and 
sulfation pattern was not possible in this study due to shortage of probe volume. As no 
plasma effluent was collected, we cannot directly demonstrate active removal of eGC 
fragments by TPE. It may also be plausible that the shift towards “control” of eGC con-
stituents and Hpa-1/Hpa-2 ratio is purely due to an equilibration of these levels within 
normal plasma (FFP levels of eGC constituents and Hpa-1/Hpa-2 levels) caused by TPE 
rather than a physiologic effect of TPE on Hpa-1/Hpa-2 ratios and a resultant reduction 
in shedding. As low dose heparin was administered in about half of the patients and 
heparin has been suggested to exert protective effects on the endothelial glycocalyx in 
pre-clinical investigations [5, 34], one could speculate on a confounding effect of heparin 
anticoagulation. However, HS concentrations were not different in patients with- and 
without heparin anticoagulation, neither before- or after TPE (data not shown). Further-
more, no data exist, investigating the effect of low dose heparin on the eGC in septic 
patients. All patients received single shot anti-allergic prophylaxis with 100 mg decortin 
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given intravenously directly before start of the TPE treatment. Glucocorticoids have 
been used in the treatment of sepsis for more than four decades, mainly for its mul-
tiple anti-inflammatory and pleiotropic effects [35]. In fact, hydrocortisone has been 
associated in pre-clinical experiments with protection of the eGC, such as in ischemia 
reperfusion injury [36, 37] and following stimulation with TNF-α [38]. However, except 
a postulated protective effect of corticosteroids on the glomerular glycocalyx [39], no 
data exist on the impact of steroids on the eGC during sepsis and septic shock. On the 
other hand, adverse effects of corticosteroid use on glycocalyx structure and endothelial 
permeability have also been reported [40, 41]. Although our study cannot exclude an 
effect of pre TPE administered glucocorticoids on the eGC, this effect has yet to be bet-
ter defined.
Conclusions
In this prospective exploratory trial, severe septic shock was associated with increased 
eGC shedding and an acquired deficiency in protective Hpa-2. Early TPE treatment par-
tially attenuated this imbalance by removing potentially injurious excessive shedding 
products while at the same time replacing the deficient eGC stabilizing enzyme Hpa-2. 
These data may not be generalizable to all patients with septic shock (i.e., with lower 
vasopressor doses) and not with less severe forms of sepsis. Whether or not an appro-
priately powered randomized controlled trial TPE might improve outcome in septic 
patients, remains to be determined.
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